![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
![[img]](http://edoc.mdc-berlin.de/style/images/fileicons/application_pdf.png) |
PDF
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
714kB |
![[img]](http://edoc.mdc-berlin.de/style/images/fileicons/image.png) |
Image (TIFF) (Figure e-1)
2MB |
![[img]](http://edoc.mdc-berlin.de/style/images/fileicons/application_msword.png) |
MS Word (e-Legend)
50kB |
| Item Type: | Article |
|---|---|
| Title: | 7T MRI in natalizumab-associated PML and ongoing MS disease activity: a case study |
| Creators Name: | Sinnecker, T. and Othman, J. and Kühl, M. and Mekle, R. and Selbig, I. and Niendorf, T. and Kunkel, A. and Wienecke, P. and Kern, P. and Paul, F. and Faiss, J. and Wuerfel, J. |
| Abstract: | OBJECTIVE: To assess the ability of ultra-high-field MRI to distinguish early progressive multifocal leukoencephalopathy (PML) from multiple sclerosis (MS) lesions in a rare case of simultaneous presentation of natalizumab-associated PML and ongoing MS activity. METHODS: Advanced neuroimaging including 1.5T, 3T, and 7T MRI with a spatial resolution of up to 0.08 mm(3) was performed. RESULTS: 7T MRI differentiated between PML-related and MS-related brain damage in vivo. Ring-enhancing MS plaques displayed a central vein, whereas confluent PML lesions were preceded by punctate or milky way-like T2 lesions. CONCLUSIONS: Given the importance of early diagnosis of treatment-associated PML, future systematic studies are warranted to assess the value of highly resolving MRI in differentiating between early PML- and MS-induced brain parenchymal lesions. |
| Source: | Neurology Neuroimmunology & Neuroinflammation |
| ISSN: | 2332-7812 |
| Publisher: | American Academy of Neurology |
| Volume: | 2 |
| Number: | 6 |
| Page Range: | e171 |
| Date: | December 2015 |
| Official Publication: | https://doi.org/10.1212/NXI.0000000000000171 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
